SEARCH

Current Location: DOTmed News > Industry Headlines > This Story

(1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Send us your Comments

 

More Industry Headlines

Varian's seven year patent dispute comes to an end Company will pay about $35 million.

FDA OKs GE's new CT scanner Ideal for challenging cases.

MRI technique can help treat concussion patients Measures white brain matter damage.

ABT's compact biomarker generator comes to Russia Ideal for the growing Russian market.

What's the big-picture impact of HIT on health care? Q&A with thought leader Bipin Thomas.

Special report: Contrast media One size does not fit all.

ClearMRI gets FDA clearance for MRI adaptor New option to extend the life of MRI systems.

Physician payment data now available CMS releases records and AMA pushes back.

Sebelius steps down from HHS post Sylvia Mathews Burwell to succeed Sebelius.

Is there a viable future for proton therapy? Yes, but challenges remain.

CyberKnife "valid option" for low-risk prostate cancer: study

by Brendon Nafziger , DOTmed News Associate Editor
A follow-up study using CyberKnife stereotactic body radiation for low-risk prostate cancer found most patients had disease-free survival after five years, with little toxicity, results that researchers say could help bolster support for the treatment.

"In our mind, it's no longer investigational or experimental therapy," study co-author Dr. Debra E. Freeman, a radiation oncologist with CyberKnife Centers of Tampa Bay in Florida, told DOTmed News. "It's a valid option in the treatment of low-risk prostate cancer."

Story Continues Below Advertisement

OiService - ISO 9001 & 13485 Certified - Call 888-673-5151

Oxford Instruments Service, is a leading ISO 9001 & 13485-certified organization,that specializes in providing quality after-market GE CT and MRI systems, serviceand parts - at prices you can afford.



CyberKnife is a robotic radiosurgery device made by Accuray Inc. of Sunnyvale, Calif., which can deliver "hypofractionated" treatments -- that is, high doses of radiation precisely sculpted to the tumor or target, and delivered in a smaller number of sessions. It was approved by the U.S. Food and Drug Administration to treat tumors anywhere in the body around nine years ago.

For the study, the patients received between 35 and 36.25 Gy in five fractions.

Freeman said slower growing, "indolent" prostate cancers are thought to respond better to hypofractionated treatment, as opposed to radiotherapy treatments where smaller doses are spread out over a longer time. "They are not exquisitely sensitive to low doses of radiation, and are more sensitive and respond more to higher doses of radiation," she said.

More aggressive, faster spreading cancers tend to be treated with lower, more frequent doses, she said.

In the study, published online this week in Radiation Oncology, researchers examined results from a pooled group of 41 patients from Stanford, Calif. and Naples, Fla., who received treatment between 2003 and 2005. The main endpoint was biochemical disease-free survival after five years, a standard measure that looks at whether prostate-specific antigen levels remain low and stable following treatment, suggesting disease is absent.

For the patients, at a median five years after therapy the biochemical disease-free survival was around 93 percent, results comparable with surgery and other forms of radiation therapy, Freeman said.

Toxic side effects from zapping the prostate were also rare, with no rectal bleeding or ulcerations, and no significant damage to the bladder, Freeman said.

"With any kind of radiation, there's a risk of some damage," she said. "You can't really get to the prostate with radiation without brushing by the bladder and the rectum on the way there. They can be injured in surgery, as well."

However, one patient did have a urologic problem, but Freeman said it was unclear if it was caused by the radiation treatment or an earlier procedure used to dilate the urethra because of difficulties passing urine.

Continue reading CyberKnife "valid option" for low-risk prostate cancer: study...
  Pages: 1 - 2 >>

Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED